HealthlineHow This Former Weightlifter Lost 80 Pounds After GLP-1s Stopped Working

A 67-year-old former competitive weightlifter pursued ESG after recurrent weight gain and self-reported limited durability with several GLP-1 medication trials. Concerns included obesity-related fatty liver disease with reported liver scarring and a family history of advanced liver disease. After ESG, his weight decreased from the 260-lb range to 178 lb, and he reported greater activity and functional capacity. The experience represents an individual treatment journey and does not establish comparative effectiveness between ESG and pharmacotherapy.

Clinical Considerations

• The patient reported more than 80 lb of weight loss after ESG, but an individual outcome cannot predict results in other patients.
• ESG was described as an incisionless endoscopic procedure that reduces functional stomach volume through suturing rather than surgical gastric resection.
• Previous GLP-1 treatment reportedly produced initial weight loss followed by diminished benefit; he continued tirzepatide for glycemic management.
• The narrative illustrates a multimodal obesity-treatment pathway involving medication, hepatology, gastroenterology, and an endoscopic intervention rather than a simple procedure-versus-drug comparison.
• The patient reported substantial dietary adjustment after ESG and a period of depression following discontinuation of his antidepressant and major changes in eating patterns.
• Much of the procedural context comes from a Boston Scientific executive, so promotional or manufacturer-associated framing should be separated from the patient’s clinical narrative.

Practice Applications

• Discuss obesity treatments as potentially sequential or complementary rather than presenting ESG and GLP-1 receptor agonists as mutually exclusive options.
• Clarify that an individual patient’s large post-ESG weight loss does not establish expected efficacy or superiority over pharmacotherapy.
• Recognize the potential importance of psychosocial adjustment when treatment substantially changes eating patterns and established routines.
• Integrate comorbid disease, previous treatment experience, patient preferences, and multidisciplinary evaluation into discussions about procedural obesity care.